SALA ISABELLA MARIA

Conforti, F., Pala, L., Catania, C., Zucali, P., Sala, I., Perrino, M., et al. (2025). Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma. CANCER, 131(18 (15 September 2025)) [10.1002/cncr.70092]. Dettaglio

Conforti, F., Bagnardi, V., Sala, I. (2025). Reply to: “Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials” and “Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer”. JOURNAL OF CLINICAL ONCOLOGY, 43(24), 2754-2756 [10.1200/JCO-25-01041]. Dettaglio

Pala, L., Merlo, F., Sala, I., Pagan, E., Oriecuia, C., Specchia, C., et al. (2025). Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 117(8), 1557-1564 [10.1093/jnci/djaf049]. Dettaglio

Conforti, F., Holtschmidt, J., Nekljudova, V., Sala, I., Pagan, E., Solbach, C., et al. (2025). Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials. THE LANCET ONCOLOGY, 26(12), 1584-1597 [10.1016/S1470-2045(25)00546-7]. Dettaglio

Canonica, G., Blasi, F., Paggiaro, P., Heffler, E., Braido, F., Brussino, L., et al. (2025). Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI). THE WORLD ALLERGY ORGANIZATION JOURNAL, 18(1) [10.1016/j.waojou.2024.101016]. Dettaglio